[go: up one dir, main page]

MX369074B - Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa. - Google Patents

Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa.

Info

Publication number
MX369074B
MX369074B MX2016012904A MX2016012904A MX369074B MX 369074 B MX369074 B MX 369074B MX 2016012904 A MX2016012904 A MX 2016012904A MX 2016012904 A MX2016012904 A MX 2016012904A MX 369074 B MX369074 B MX 369074B
Authority
MX
Mexico
Prior art keywords
chromene
pyridopyrazinediones
tetrahydrocyclopropa
gamma
compounds
Prior art date
Application number
MX2016012904A
Other languages
English (en)
Other versions
MX2016012904A (es
Inventor
Robert Verhoest Patrick
William Am Ende Christopher
Michael Humphrey John
Scott Johnson Douglas
Wayne Kauffman Gregory
Antonia Rankic Danica
Friederike Stepan Antonia
Youngjing PETTERSSON Martin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369074(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016012904A publication Critical patent/MX2016012904A/es
Publication of MX369074B publication Critical patent/MX369074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos y las sales farmacéuticamente aceptables de los mismos se describen, en donde los compuestos tienen la estructura de la Fórmula I (ver Fórmula) en X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, como se define en la especificación. Las composiciones farmacéuticas correspondientes, métodos de tratamiento, métodos de síntesis, e intermediarios también se describen.
MX2016012904A 2014-04-01 2015-03-18 Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa. MX369074B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Publications (2)

Publication Number Publication Date
MX2016012904A MX2016012904A (es) 2016-12-07
MX369074B true MX369074B (es) 2019-10-28

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012904A MX369074B (es) 2014-04-01 2015-03-18 Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa.

Country Status (30)

Country Link
US (2) US20150274721A1 (es)
EP (1) EP3126361B1 (es)
JP (1) JP6643247B2 (es)
KR (1) KR101886945B1 (es)
CN (1) CN106211770B (es)
AP (1) AP2016009465A0 (es)
AR (1) AR099874A1 (es)
AU (1) AU2015242330B2 (es)
BR (1) BR112016022519A8 (es)
CA (1) CA2944308A1 (es)
CL (1) CL2016002422A1 (es)
CR (1) CR20160454A (es)
CU (1) CU20160140A7 (es)
DK (1) DK3126361T3 (es)
DO (1) DOP2016000266A (es)
EA (1) EA031419B1 (es)
EC (1) ECSP16078289A (es)
ES (1) ES2759277T3 (es)
HK (1) HK1231481A1 (es)
IL (1) IL248154B (es)
MD (1) MD20160102A2 (es)
MX (1) MX369074B (es)
NI (1) NI201600149A (es)
PE (1) PE20161364A1 (es)
PH (1) PH12016501864A1 (es)
SG (1) SG11201607465UA (es)
TW (1) TWI568733B (es)
UY (1) UY36054A (es)
WO (1) WO2015150957A1 (es)
ZA (1) ZA201606252B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
ES2818806T3 (es) * 2015-02-03 2021-04-14 Pfizer Novedosas ciclopropabenzofuranil piridopirazindionas
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
US10925872B2 (en) 2016-12-16 2021-02-23 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
TWI838401B (zh) * 2018-09-12 2024-04-11 瑞士商諾華公司 抗病毒性吡啶并吡𠯤二酮化合物
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
TW202100526A (zh) 2019-03-06 2021-01-01 日商第一三共股份有限公司 吡咯并吡唑衍生物
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6929808B2 (en) 2000-11-03 2005-08-16 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
CN1315832C (zh) * 2002-02-28 2007-05-16 沙诺费－阿方蒂 杂芳基取代的2－吡啶基和2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮衍生物
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
AU2003279216A1 (en) 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
EP1899296B1 (en) 2005-06-22 2010-11-17 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
MX2008012456A (es) 2006-04-21 2008-10-10 Pfizer Prod Inc Piridin[3,4-b]pirazinonas.
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CN101631545B (zh) 2007-01-22 2013-03-13 辉瑞产品公司 治疗性化合物的甲苯磺酸盐及其药物组合物
EP2355659A4 (en) * 2008-10-23 2012-10-10 Merck Sharp & Dohme M1 RECEPTOR MODULATORS CONCEALED HETEROCYCLIC POSITIVE ALLOSTERIC
CA2830027C (en) 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
KR102096625B1 (ko) * 2012-05-16 2020-04-03 얀센 파마슈티칼즈, 인코포레이티드 (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN104936958B (zh) * 2013-01-17 2019-07-26 詹森药业有限公司 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物
JP6425717B2 (ja) * 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン

Also Published As

Publication number Publication date
CL2016002422A1 (es) 2017-02-03
US20170166566A1 (en) 2017-06-15
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
AU2015242330B2 (en) 2017-08-17
AU2015242330A1 (en) 2016-09-22
US20150274721A1 (en) 2015-10-01
PE20161364A1 (es) 2016-12-25
EP3126361B1 (en) 2019-11-06
IL248154A0 (en) 2016-11-30
BR112016022519A8 (pt) 2018-03-06
EA031419B1 (ru) 2018-12-28
TWI568733B (zh) 2017-02-01
JP2017512803A (ja) 2017-05-25
TW201540716A (zh) 2015-11-01
JP6643247B2 (ja) 2020-02-12
AR099874A1 (es) 2016-08-24
CU20160140A7 (es) 2017-02-02
ECSP16078289A (es) 2017-02-24
AP2016009465A0 (en) 2016-09-30
MD20160102A2 (ro) 2017-04-30
HK1231481A1 (zh) 2017-12-22
BR112016022519A2 (pt) 2017-08-15
CA2944308A1 (en) 2015-10-08
ZA201606252B (en) 2018-05-30
CN106211770A (zh) 2016-12-07
CN106211770B (zh) 2018-02-06
DK3126361T3 (da) 2020-01-02
NI201600149A (es) 2016-11-18
DOP2016000266A (es) 2016-11-15
EP3126361A1 (en) 2017-02-08
KR20160137635A (ko) 2016-11-30
KR101886945B1 (ko) 2018-08-08
CR20160454A (es) 2016-12-06
IL248154B (en) 2020-09-30
EA201600619A1 (ru) 2017-03-31
ES2759277T3 (es) 2020-05-08
SG11201607465UA (en) 2016-10-28
UY36054A (es) 2015-10-30
MX2016012904A (es) 2016-12-07

Similar Documents

Publication Publication Date Title
PH12016501864A1 (en) Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MY176357A (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
MY190408A (en) Compositions and methods for treating cns disorders
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
MX2016013329A (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017500089A1 (en) Aldosterone synthase inhibitors
PH12017501369A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2018015548A (es) Inhibidores mitocondriales para el tratamiento de trastornos de proliferacion.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
PH12017501134A1 (en) Fumagillol derivatives
MX2019000608A (es) Derivados de panteteina para tratamiento de trastornos neurologicos.
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6

Legal Events

Date Code Title Description
FG Grant or registration